Morris James continues its investigation into claims that long-term use of Depo-Provera may be linked to meningiomas, slow-growing but serious brain tumors. As lawsuits against Pfizer, the manufacturer of Depo-Provera, gain momentum, the Judicial Panel on Multidistrict Litigation (JPML) is expected to decide whether to consolidate these cases into a multidistrict litigation (MDL). This decision will shape the course of litigation for affected individuals nationwide.
Depo-Provera is a widely used injectable contraceptive that contains medroxyprogesterone acetate (MPA), a synthetic hormone. Emerging evidence suggests that prolonged use may increase the risk of developing intracranial meningiomas, which can lead to severe neurological symptoms. Meningiomas are noncancerous brain tumors that can cause debilitating health issues, including headaches, vision problems, and cognitive impairments.
Many women who developed these tumors after extended Depo-Provera use are now seeking legal action, alleging that Pfizer failed to adequately warn the public about the potential risks. Studies have shown that the risk of developing meningiomas increases with higher cumulative doses of medroxyprogesterone acetate, particularly for those who have used Depo-Provera for years.
Currently, at least 22 lawsuits have been filed by individuals diagnosed with meningiomas after using Depo-Provera. Plaintiffs have petitioned for the cases to be consolidated into an MDL in the U.S. District Court for the Northern District of California, citing favorable consumer protection laws. Pfizer, however, is pushing for the litigation to be centralized in the Southern District of New York, where the company is headquartered.
The JPML’s decision, expected imminently, will determine where these cases move forward and how pretrial proceedings will be handled. An MDL can streamline litigation by consolidating pretrial discovery, reducing legal costs, and ensuring consistency in court rulings.
Legal analysts expect the number of lawsuits to grow significantly in 2025, with more individuals coming forward as awareness of the link between Depo-Provera and meningiomas spreads. Recent international research and regulatory actions have further highlighted the concerns surrounding the long-term use of this drug, reinforcing the urgency of these legal proceedings.
If you or a loved one developed a meningioma after prolonged use of Depo-Provera, you may be eligible to file a lawsuit. Signs of meningioma include:
Women who have been diagnosed with meningiomas after using Depo-Provera may be entitled to compensation for medical expenses, lost wages, pain and suffering, and other damages.
At Morris James, our experienced Depo-Provera Litigation Attorneys are dedicated to holding corporations accountable for failing to disclose health risks. With a strong history of handling complex product liability claims, we have the knowledge and resources needed to advocate for individuals harmed by dangerous drugs.
If you have suffered health complications linked to Depo-Provera, now is the time to take action. Call us today at 302.655.2599 for a free, confidential consultation. Our rapid response legal team is ready to fight for your rights and help you secure the compensation you deserve.
Contact us now to discuss your case.
The JPML’s decision, expected imminently, will determine where these cases move forward and how pretrial proceedings will be handled. An MDL can streamline litigation by consolidating pretrial discovery, reducing legal costs, and ensuring consistency in court rulings.
